Galvus (vitagliptin)
PreclinicalSmall molecule
Galvus (vitagliptin) is one of 13 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Micardis
Boehringer IngelheimApproved
Fosamax
OOrganon and Co
Approved
Prolia
OOrganon and Co
Approved
Tricor
JJagotec
Phase 2
Efruxifermin
Akero TherapeuticsPhase 3
Niacor
AbbViePreclinical
Trulicity
Eli LillyPreclinical
Invokana
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Galvus (vitagliptin). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKorea University Anam Hospital